In recent years, the global biopharmaceutical industry is developing rapidly. With a statistical analysis of the patents, this paper analyzes the current situation and the trend of the biopharma development, the focuses and the hotspots of the technological development, to provide a reference for the industrial decision-making and policy-making. The analysis shows that the global biopharma development is quite mature, and the development of anti-cancer drugs is still a hot spot in recent years. The United States is the innovation representative and the patent applications in China increase in recent years, though the quality remains to be improved. Companies are still the main force in the drug research and development, and the scientific research institutions are constantly providing new impetus to the biopharma industry. The CRISPR-Cas system, the PD-1/PD-L1 immunotherapy and the CAR T -cell therapy are leading technologies in this field.
WANG Chunli
,
HUANG Yaoqing
,
LI Ziyan
,
MAO Yanyan
. Analysis of patents in global biopharmaceutical industry[J]. Science & Technology Review, 2021
, 39(2)
: 73
-82
.
DOI: 10.3981/j.issn.1000-7857.2021.02.018
[1] World Health Organization. The top 10 causes of death[EB/OL]. (2018-05-24)[2018-05-24]. https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causesof-death.
[2] Lisa U. Top companies and drugs by sales in 2019[J]. Nature Reviews Drug Discovery, 2020(228):19.
[3] 谢华玲, 陈芳, Cynthia, 等. 全球生物制药领域研发态势分析[J]. 中国生物工程杂志, 2019, 39(5):1-10.
[4] 谌凯, 应向伟, 吴叶青, 等. 基于专利分析和文献计量的中国医药制造业发展态势研究[J]. 科技管理研究, 2018, 38(2):103-111.
[5] 齐燕, 高东平, 杨渊. 中国医药专利70年发展态势分析[J]. 医学信息学杂志, 2019, 40(10):19-24.
[6] 赵杨升, 徐俐颖, 褚淑贞. 中国医药制造业专利合作发展研究与分析[J]. 药学进展, 2019, 43(8):621-627.
[7] 刘畅, 李硕, 李凤新, 等. 生物医药产业专利态势分析[J]. 科学观察, 2012, 7(4):40-43.
[8] 傅俊英, 赵蕴华. 中国生物医药专利的分布及趋势分析[J]. 现代生物医学进展, 2012, 12(1):142-150.
[9] Wright A V, Nuñez J K, Doudna J A. Biology and applications of CRISPR systems:Harnessing nature's toolbox for genome engineering[J]. Cell, 2016, 164(1):29-44.
[10] Liang P P, Xu Y W, Zhang X Y, et al. CRISPR/Cas9mediated gene editing in human tripronuclear zygotes[J]. Protein & Cell, 2015, 6(5):363-372.
[11] Cyranoski D. Chinese scientists to pioneer first human CRISPR trial[J]. Nature, 2016, 535(7613):476-477.
[12] Nature. Quest to use CRISPR against disease gains ground[EB/OL]. (2020-01-06)[2020-01-06]. https://www.nature.com/articles/d41586-019-03919-0.
[13] Longo D L, Boussiotis V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. New England Journal of Medicine, 2016, 375(18):1767-1778.
[14] Tang J, Yu J X, Hubbard-Lucey V M, et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors[J]. Nature Reviews Drug Discovery, 2018(17):854-855.
[15] Yip A, Webster R M. The market for chimeric antigen receptor T cell therapies[J]. Nature Reviews Drug Discovery, 2018(17):161-162.
